Anika reports fourth quarter and year-end 2023 financial results

Revenue growth and adjusted ebitda1 exceeded expectations in the fourth quarter and full year oa pain management achieved record annual revenues of $102 million, up 11% in 2023 announces cost reduction initiatives providing annualized savings of approximately $10 million anika positioned to generate adjusted ebitda1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted ebitda1 margin of at least 15% bedford, mass., march 13, 2024 (globe newswire) -- anika therapeutics, inc. (nasdaq: anik), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended december 31, 2023.
ANIK Ratings Summary
ANIK Quant Ranking